共 44 条
New Bioabsorbable Septal Repair Implant for Percutaneous Closure of a Patent Foramen Ovale: Short-Term Results of a Single-Centre Experience
被引:10
作者:
Van den Branden, B. J. L.
[1
]
Post, M. C.
[1
]
Jaarsma, W.
[1
]
ten Berg, J. M.
[1
]
Suttorp, M. J.
[1
]
机构:
[1] St Antonius Hosp, Dept Cardiol, NL-3435 CM Nieuwegein, Netherlands
关键词:
congenital heart defect;
catheterization;
efficacy;
TRANSCATHETER CLOSURE;
PARADOXICAL EMBOLISM;
FOLLOW-UP;
DEVICE;
OCCLUDER;
AMPLATZER;
EVENTS;
STROKE;
RISK;
COMPLICATIONS;
D O I:
10.1002/ccd.21998
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Background: Permanent implants for closure of a patent foramen ovale (PFO) have a number of possible disadvantages including erosions, thrombus formation, and allergic reactions. The incidence of adverse events may be lower using a bioabsorbable device. Objective: To evaluate the short-term safety and efficacy of a new bioabsorbable closure device. Methods: All 35 consecutive patients (21 female, mean age 47.9 +/- 10.8 years), who underwent a percutaneous PFO closure between November 2007 and July 2008, were included. All complications were reported. The efficacy was based on the residual shunting the day after implant and at 1 month follow-up and was graded as minimal, moderate, or severe, using contrast transthoracic echocardiography with the Valsalva manoeuvre. Results: The only in-hospital complication was a surgical device retrieval from the femoral vein. Four patients developed a minimal inguinal haematoma. One day after closure, residual shunting was present in 56% of the patients (minimal 27%, moderate 23% and severe 6%). At I month follow-up (n = 33), one patient developed a transient neurological deficit and three patients suffered from paroxysmal atrial fibrillation. A residual shunt at 1 month was present in 45% of the patients (minimal 30%, moderate 12%, and severe 3%). Conclusions: Percutaneous PFO closure using the bioabsorbable closure device seems to be safe. However, a high rate of residual shunting is present at 1 month follow-up. Long-term follow-up data are necessary to evaluate the efficacy and safety of this device. (C) 2009 Wiley-Liss, Inc.
引用
收藏
页码:286 / 290
页数:5
相关论文
共 44 条